Kidswell Bio Corporation · TSE:4584
Kidswell Bio — Q3 FY2024 Earnings Presentation
16 slides from Kidswell Bio's earnings presentation, Feb 12, 2025
Slide 1: Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025
Biotech Striving for Value Creation - For a Comprehensive Healthcare System for Children, Families, and Society - Security Code: 4584 Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 February 12, 2025 Kidswell Bio Corporation © 2025 Kidswell Bio Corporation. 1
Slide 2: Agenda
◆ Financial Highlights and Forecasts Agenda ◆ Initiatives in Maximizing Corporate Value © 2025 Kidswell Bio Corporation. 2
Slide 3: Financial Highlights and Forecasts
Financial Highlights and Forecasts © 2025 Kidswell Bio Corporation. 3
Slide 4: Income Statement
Income Statement (Unit: thousand yen) FY2023 FY2024 FY2024 Subject 3Q Results 3Q Results 3Q Results Year-on- KWB Non-consolidated (non-consolidated) (consolidated) year ratio (non-consolidated) Gross sales 1,566,742 3,036,304 194% 3,034,828 Cost of goods sold 703,808 2,005,685 285% 2,005,686 Gross p
Slide 5: Balance Sheet
Balance Sheet (Unit: thousand yen) Subject 4Q FY2024 (non-consolidated) 3Q FY2025 (consolidated) Current assets 4,924,221 4,069,237 (Cash and cash equivalents) 2,231,411 1,318,255 (Accounts receivable) 881,407 131,937 (Products) -- -- (In-process inventory) 875,654 990,617 (Advance payments) 739,567
Slide 6: Impact of foreign exchange fluctuations on business performance
Impact of foreign exchange fluctuations on business performance • Gross profit margin: All biosimilar APIs are manufactured overseas, so exchange rate fluctuations have a direct impact ➢ The sharp depreciation of the yen since 2022 has led to an increase in cost of sales in USD, paid in JPY and a si
Slide 7: Impact of inflation on business performance
Impact of inflation on business performance • Global price increases have driven up the cost of labor, supplies and raw materials required to manufacture biosimilars, resulting in lower profitability for the biosimilar business • The pace of price increases is gradually slowing and the increase in m
Slide 8: Outlook for the current fiscal year (ending March 31, 2025)
Outlook for the current fiscal year (ending March 31, 2025) Keep manufacturing and delivery of biosimilar APIs and formulations according to the schedule agreed with partner pharmaceutical companies. Improve the gross profit margin of the biosimilar business as a result of efforts to address issues
Slide 9: Initiatives in Maximizing Corporate Value
Initiatives in Maximizing Corporate Value © 2025 Kidswell Bio Corporation. 9
Slide 10: Planned key initiatives: Biosimilars (KWB)
Planned key initiatives: Biosimilars (KWB) FY2024 FY2025 Initiative Progress (current FY) (next FY) Maintaining stable supply through Manufacturing and delivery are progressing adjustments to the manufacturing according to the schedule agreed with schedule and addressing deviations partner pharmaceu
Slide 11: Planned key initiatives: Cell therapy (S-Quatre)
Planned key initiatives: Cell therapy (S-Quatre) FY2024 FY2025 Initiative Progress (current FY) (next FY) 1st & 2nd case: 24 weeks after administration, the patient is doing well Supporting clinical research at Nagoya 3rd case: waiting for the baby tooth to fall out University for cerebral palsy The
Slide 12: Planned key initiatives: Group-wide management strategy
Planned key initiatives: Group-wide FY2024 FY2025 Initiative Progress (current FY) (next FY) • Reviewing evaluation system in alignment with 1. Efficient Restruction of corporate FY2023 organizational restructuring utilization of culture and systems • Promote the recruitment of human resources and r
Slide 13: Business forecast and events expected to impact the share price
Business forecast and events expected to impact the share price • Improve the profitability of marketed biosimilar products aiming to show positive operating profit in FY2026 as a group and maximize the amount of the profitability • Increase the values of both Biosimilar business and Cell Therapy bu
Slide 14: IR Schedule for FY2024 (tentative)
IR Schedule for FY2024 (tentative) IR Basic Policy • Improve communication with shareholders and investors to enhance their understanding of KWB and enable them to evaluate KWB appropriately • Improve the quality of the information provided instead of simply providing frequent briefings 1Q 2Q 3Q 4Q
Slide 15: KIDS WELL, ALL WELL
KIDS WELL, ALL WELL All for Kids, Kids for All © 2025 Kidswell Bio Corporation. 15
Slide 16: Information material notice and forward-looking statements
This information material is provided for understanding Kidswell Bio Corporation (“KWB”), not for soliciting investment in KWB shares. Information provided in this material may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts, and assumpti